ArticleAlimentary pharmacology & therapeutics2013
Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 5 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns.Infection · 2024Pooled it
- The incidence rate of herpes zoster in inflammatory bowel disease: A meta-analysis of cohort studies.Medicine · 2021Pooled it
- Immunosuppression as a risk factor for COVID-19: a meta-analysis.Internal medicine journal · 2021Pooled it
- Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Pooled it
- ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.The American journal of gastroenterology · 2017Guideline
- Web-Based Video Education to Improve Uptake of Influenza Vaccination and Other Preventive Health Recommendations in Adults With Inflammatory Bowel Disease: Randomized Controlled Trial of Project PREVENT.Journal of medical Internet research · 2023Trial
- Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.Inflammatory bowel diseases · 2023Trial
- Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.Journal of Crohn's & colitis · 2021Trial
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.Inflammatory bowel diseases · 2018Trial
- Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study.Human vaccines & immunotherapeutics · 2026Article
- Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.World journal of virology · 2026Review
- Real-World Safety and Herpes Zoster Outcomes After Recombinant Zoster Vaccination in Inflammatory Bowel Disease.Journal of clinical medicine · 2026Article
- Risk of herpes zoster among adults in the United States initiating immunosuppressive therapy: A retrospective cohort study.Journal of managed care & specialty pharmacy · 2026Article
- Elevated Risk of Herpes Zoster in Vitiligo Patients: A Nationwide Population-Based Cohort Study of Taiwan.The Journal of dermatology · 2026Article
- Influenza vaccine uptake among patients with inflammatory bowel disease: comparable outcomes between telemedicine and in-person care.Crohn's & colitis 360 · 2026Article
- Herpes zoster frequency and severity in immunocompromised pediatric populations: a structured narrative review.Frontiers in pediatrics · 2026Review
- Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases.The Journal of infectious diseases · 2025Article
- Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.Human vaccines & immunotherapeutics · 2025Article
- Herpes zoster infection in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025Review
- Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients.Diseases (Basel, Switzerland) · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatients with inflammatory bowel disease (IBD) on certain immunosuppressants have increased herpes zoster (HZ) risk.
aimTo determine the risk of HZ in IBD and how antitumour necrosis factor-alpha (anti-TNF) agents affect this risk.
methodsWe performed a retrospective cohort and nested case-control study using administrative data from IMS LifeLink(®) Information Assets-Health Plan Claims Database. In the cohort, we identified IBD patients <age 64 by diagnosis codes; matched to four individuals without IBD. HZ risk was evaluated by incidence rate ratio (IRR) and adjusted Cox proportional hazards models (HR). In the nested case-control analysis, 2659 IBD patients with HZ were each matched to four IBD patients without HZ. We determined associations between medications and HZ using conditional logistic regression.
resultsThe cohort included 50 932 patients with Crohn's disease (CD), 56 403 patients with ulcerative colitis (UC) and 1269 with unspecified IBD, matched to 434 416 individuals without IBD. The IBD cohort had increased HZ risk compared with non-IBD (IRR: 1.68, 95% CI: 1.60-1.76). After adjustment, IBD patients had a higher risk of HZ than non-IBD (HR: 1.49, 95% CI: 1.42-1.57). In the nested case-control multivariate-adjusted analyses, anti-TNF medications (OR: 1.81, 95% CI: 1.48-2.21), corticosteroids (OR: 1.73, 95% CI: 1.51-1.99) and thiopurines (OR: 1.85, 95% CI: 1.61-2.13) were independently associated with HZ. Risk of HZ was highest with combination anti-TNF and thiopurine therapy (OR: 3.29, 95% CI: 2.33-4.65).
conclusionsPatients with inflammatory bowel disease are at increased risk for herpes zoster. Use of thiopurines, anti-TNF agents, combination therapy and corticosteroids increases herpes zoster risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.